Anne N. Nafziger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Anne N. Nafziger has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Joseph S. Bertino
Clinical Pharmacology Research Center, Bassett Healthcare, Cooperstown, New York
5 shared publications Angela D. M. Kashuba
3 shared publicationsAngelica I. Goss-Bley
3 shared publicationsJoseph S. Bertino
Bertino Consulting
3 shared publications- Kristina Lindvall
Department of Public Health and Clinical Medicine, Epidemiology and Global Health, Umeå University, S-901 87 Umeå, Sweden
2 shared publications - Margareta Norberg
Department of Public Health and clinical Medicine, Umea University, Umea, Sweden
2 shared publications
Latest Publications
- 1 June 2016
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 38 (3) , 383-387
S-Warfarin Limited Sampling Models to Estimate Area Under the Concentration Versus Time Curve for Cytochrome P450 2C9 Baseline Activity and After Induction
Phenotyping cytochrome P450 (CYP) 2C9 activity using S-warfarin has routinely required extensive blood sampling over at least 96 hours post dose to estimate the area under the concentration time curve from zero to infinity (AUC). Alternatively, S-warfarin limited sampling models (LSMs) using one or two concentration time-points have been proposed to estimate AUC.This study evaluated whether S-warfarin LSMs accurately estimate CYP2C9 baseline and induction conditions in healthy adults and in advanced stage cancer patients.Plasma S-warfarin concentrations from healthy adults (n=92) and in advanced stage cancer patients (n=22) were obtained from six published studies where a single 10 mg dose of oral warfarin was administered at CYP2C9 baseline and induction conditions. S-warfarin observed AUC was determined by noncompartmental analysis, while estimated AUC was calculated from the LSMs. Bias and precision were assessed by percent mean prediction error (%MPE), percent mean absolute error (%MAE), and percent root mean square error (%RMSE).Different results were observed for S-warfarin LSMs in estimating CYP2C9 baseline activity, with the majority of studies resulting in unacceptable bias and precision. The %MPE, %MAE, and/or %RMSE exceeded acceptable limits for LSMs in advanced stage cancer patients and during CYP2C9 induction with lopinavir/ritonavir.The differing results during CYP2C9 baseline conditions, as well as unacceptable bias and precision in patients with advanced cancer and during CYP2C9 induction, considerably limit the widespread use of previously published S-warfarin LSMs.
- 1 June 2016
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 38 (3) , 383-387
S-Warfarin Limited Sampling Models to Estimate Area Under the Concentration Versus Time Curve for Cytochrome P450 2C9 Baseline Activity and After Induction
Phenotyping cytochrome P450 (CYP) 2C9 activity using S-warfarin has routinely required extensive blood sampling over at least 96 hours post dose to estimate the area under the concentration time curve from zero to infinity (AUC). Alternatively, S-warfarin limited sampling models (LSMs) using one or two concentration time-points have been proposed to estimate AUC.This study evaluated whether S-warfarin LSMs accurately estimate CYP2C9 baseline and induction conditions in healthy adults and in advanced stage cancer patients.Plasma S-warfarin concentrations from healthy adults (n=92) and in advanced stage cancer patients (n=22) were obtained from six published studies where a single 10 mg dose of oral warfarin was administered at CYP2C9 baseline and induction conditions. S-warfarin observed AUC was determined by noncompartmental analysis, while estimated AUC was calculated from the LSMs. Bias and precision were assessed by percent mean prediction error (%MPE), percent mean absolute error (%MAE), and percent root mean square error (%RMSE).Different results were observed for S-warfarin LSMs in estimating CYP2C9 baseline activity, with the majority of studies resulting in unacceptable bias and precision. The %MPE, %MAE, and/or %RMSE exceeded acceptable limits for LSMs in advanced stage cancer patients and during CYP2C9 induction with lopinavir/ritonavir.The differing results during CYP2C9 baseline conditions, as well as unacceptable bias and precision in patients with advanced cancer and during CYP2C9 induction, considerably limit the widespread use of previously published S-warfarin LSMs.
- Open Access
- 30 September 2011
- Published by Springer Nature in BMC Public Health
- Vol. 11 (1) , 748
Self-rated health does not predict 10-year weight change among middle-aged adults in a longitudinal population study
There is a worldwide obesity epidemic, but lack of a simple method, applicable for research or clinical use, to identify individuals at high risk of weight gain. Therefore, the relationship of self-rated health and 10-year percent weight change was evaluated to determine if self-rated health would predict weight change.
- 30 September 2011
- Published by Springer Nature in BMC Public Health
- Vol. 11 (1) , 748
Open AccessSelf-rated health does not predict 10-year weight change among middle-aged adults in a longitudinal population study
There is a worldwide obesity epidemic, but lack of a simple method, applicable for research or clinical use, to identify individuals at high risk of weight gain. Therefore, the relationship of self-rated health and 10-year percent weight change was evaluated to determine if self-rated health would predict weight change.
- 15 July 2011
- Published by Springer Nature
- p. 631-653
Probe Cocktail Studies
- 1 June 2010
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 50 (6) , 614-622
Desirudin Dosing and Monitoring in Moderate Renal Impairment
Desirudin is a renally eliminated direct thrombin inhibitor approved to prevent venous thromboembolism. Empiric dosage adjustment and activated partial thromboplastin time (aPTT) monitoring in patien...
- 1 June 2010
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 50 (6) , 614-622
Desirudin Dosing and Monitoring in Moderate Renal Impairment
Desirudin is a renally eliminated direct thrombin inhibitor approved to prevent venous thromboembolism. Empiric dosage adjustment and activated partial thromboplastin time (aPTT) monitoring in patien...
- Open Access
- 12 June 2007
- Published by Springer Nature in BMC Public Health
- Vol. 7 (1) , 108
Who is maintaining weight in a middle-aged population in Sweden? A longitudinal analysis over 10 years
Obesity has primarily been addressed with interventions to promote weight loss and these have been largely unsuccessful. Primary prevention of obesity through support of weight maintenance may be a preferable strategy although to date this has not been the main focus of public health interventions. The aim of this study is to characterize who is not gaining weight during a 10 year period in Sweden. Cross-sectional and longitudinal studies were conducted in adults aged 30, 40, 50 and 60 years during the Västerbotten Intervention Programme in Sweden. Height, weight, demographics and selected cardiovascular risk factors were collected on each participant. Prevalences of obesity were calculated for the 40, 50 and 60 year olds from the cross-sectional studies between 1990 and 2004. In the longitudinal study, 10-year non-gain (lost weight or maintained body weight within 3% of baseline weight) or weight gain (≥ 3%) was calculated for individuals aged 30, 40, or 50 years at baseline. A multivariate logistic regression model was built to predict weight non-gain. There were 82,927 adults included in the cross-sectional studies which had an average annual participation rate of 63%. Prevalence of obesity [body mass index (BMI) in kg/m2 ≥ 30] increased from 9.4% in 1990 to 17.5% in 2004, and 60 year olds had the highest prevalence of obesity. 14,867 adults with a BMI of 18.5–29.9 at baseline participated in the longitudinal surveys which had a participation rate of 74%. 5242 adults (35.3%) were categorized as non-gainers. Older age, being female, classified as overweight by baseline BMI, later survey year, baseline diagnosis of diabetes, and lack of snuff use increased the chances of not gaining weight. Educational efforts should be broadened to include those adults who are usually considered to be at low risk for weight gain – younger individuals, those of normal body weight, and those without health conditions (e.g. diabetes type 2) and cardiovascular risk factors – as these are the individuals who are least likely to maintain their body weight over a 10 year period. The importance of focusing obesity prevention efforts on such individuals has not been widely recognized.
- 12 June 2007
- Published by Springer Nature in BMC Public Health
- Vol. 7 (1) , 108
Open AccessWho is maintaining weight in a middle-aged population in Sweden? A longitudinal analysis over 10 years
Obesity has primarily been addressed with interventions to promote weight loss and these have been largely unsuccessful. Primary prevention of obesity through support of weight maintenance may be a preferable strategy although to date this has not been the main focus of public health interventions. The aim of this study is to characterize who is not gaining weight during a 10 year period in Sweden. Cross-sectional and longitudinal studies were conducted in adults aged 30, 40, 50 and 60 years during the Västerbotten Intervention Programme in Sweden. Height, weight, demographics and selected cardiovascular risk factors were collected on each participant. Prevalences of obesity were calculated for the 40, 50 and 60 year olds from the cross-sectional studies between 1990 and 2004. In the longitudinal study, 10-year non-gain (lost weight or maintained body weight within 3% of baseline weight) or weight gain (≥ 3%) was calculated for individuals aged 30, 40, or 50 years at baseline. A multivariate logistic regression model was built to predict weight non-gain. There were 82,927 adults included in the cross-sectional studies which had an average annual participation rate of 63%. Prevalence of obesity [body mass index (BMI) in kg/m2 ≥ 30] increased from 9.4% in 1990 to 17.5% in 2004, and 60 year olds had the highest prevalence of obesity. 14,867 adults with a BMI of 18.5–29.9 at baseline participated in the longitudinal surveys which had a participation rate of 74%. 5242 adults (35.3%) were categorized as non-gainers. Older age, being female, classified as overweight by baseline BMI, later survey year, baseline diagnosis of diabetes, and lack of snuff use increased the chances of not gaining weight. Educational efforts should be broadened to include those adults who are usually considered to be at low risk for weight gain – younger individuals, those of normal body weight, and those without health conditions (e.g. diabetes type 2) and cardiovascular risk factors – as these are the individuals who are least likely to maintain their body weight over a 10 year period. The importance of focusing obesity prevention efforts on such individuals has not been widely recognized.
- 22 August 2002
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 72 (2) , 192-199
Effect of sex and menstrual cycle phase on cytochrome P450 2C19 activity with omeprazole used as a biomarker
Background: Literature addressing the effect of sex on cytochrome P450 (CYP) 2C19 activity is conflicting. The exogenous female sex steroid hormones used in oral contraceptives are believed to significantly inhibit CYP2C19 activity. However, the effect of variations in endogenous sex steroid concentrations throughout the menstrual cycle has not been investigated.Objective: The objective of this study was to determine the effects of sex and menstrual cycle phase on CYP2C19 activity by using omeprazole.Methods: White subjects with body weights between 45 and 66 kg received a single oral dose of 30 mg omeprazole. Those with weights of 67 to 90 kg received a dose of 40 mg. Twelve female subjects were phenotyped during the midfollicular and midluteal phases of the menstrual cycle for 3 complete cycles. Twelve male subjects were phenotyped every 14 days for 12 weeks. The 2‐hour postdose plasma concentration ratio of omeprazole to 5′‐hydroxyomeprazole was used as a measure of CYP2C19 activity. All subjects were genotyped for CYP2C19*2 and *3 alleles.Results: Twelve women and 8 men were extensive metabolizers (EMs) with a CYP2C19*1/*1 genotype, whereas 4 male subjects were heterozygous (CYP2C19*1/*2). Median metabolic ratios during the midfollicular and midluteal visits were 0.845 and 0.930, respectively (P = .7). Sex had no effect on CYP2C19 activity in CYP2C19*1/*1 EMs (0.875 for men versus 1.070 for women, P = .140). The median metabolic ratios of all individuals with 2C19*1/*1 and *1/*2 genotypes were 0.94 and 3.75, respectively.Conclusion: There is no sex difference in CYP2C19 activity in healthy white CYP2C19*1/*1 EMs with the omeprazole ratios. A gene‐dose effect was observed. In addition, variations in endogenous sex steroid concentrations throughout the menstrual cycle did not influence CYP2C19 activity.Clinical Pharmacology & Therapeutics (2002) 72, 192–199; doi: 10.1067/mcp.2002.126174
- 22 August 2002
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 72 (2) , 192-199
Effect of sex and menstrual cycle phase on cytochrome P450 2C19 activity with omeprazole used as a biomarker
Background: Literature addressing the effect of sex on cytochrome P450 (CYP) 2C19 activity is conflicting. The exogenous female sex steroid hormones used in oral contraceptives are believed to significantly inhibit CYP2C19 activity. However, the effect of variations in endogenous sex steroid concentrations throughout the menstrual cycle has not been investigated.Objective: The objective of this study was to determine the effects of sex and menstrual cycle phase on CYP2C19 activity by using omeprazole.Methods: White subjects with body weights between 45 and 66 kg received a single oral dose of 30 mg omeprazole. Those with weights of 67 to 90 kg received a dose of 40 mg. Twelve female subjects were phenotyped during the midfollicular and midluteal phases of the menstrual cycle for 3 complete cycles. Twelve male subjects were phenotyped every 14 days for 12 weeks. The 2‐hour postdose plasma concentration ratio of omeprazole to 5′‐hydroxyomeprazole was used as a measure of CYP2C19 activity. All subjects were genotyped for CYP2C19*2 and *3 alleles.Results: Twelve women and 8 men were extensive metabolizers (EMs) with a CYP2C19*1/*1 genotype, whereas 4 male subjects were heterozygous (CYP2C19*1/*2). Median metabolic ratios during the midfollicular and midluteal visits were 0.845 and 0.930, respectively (P = .7). Sex had no effect on CYP2C19 activity in CYP2C19*1/*1 EMs (0.875 for men versus 1.070 for women, P = .140). The median metabolic ratios of all individuals with 2C19*1/*1 and *1/*2 genotypes were 0.94 and 3.75, respectively.Conclusion: There is no sex difference in CYP2C19 activity in healthy white CYP2C19*1/*1 EMs with the omeprazole ratios. A gene‐dose effect was observed. In addition, variations in endogenous sex steroid concentrations throughout the menstrual cycle did not influence CYP2C19 activity.Clinical Pharmacology & Therapeutics (2002) 72, 192–199; doi: 10.1067/mcp.2002.126174
- 1 April 2002
- Vol. 42 (4) , 376-82
Limited sampling strategy to predict AUC of the CYP3A phenotyping probe midazolam in adults: application to various assay techniques.
Midazolam clearance is used to phenotype hepatic CYP3A activity but requires multiple plasma samples following a single intravenous dose. The authors evaluated the use of a limited sampling scheme, using different assay techniques to determine the reproducibility of such a strategy in estimating midazolam AUC. Seventy-three healthy adults received midazolam as a single intravenous bolus dose. At least eight plasma samples were collected from each subject and were assayed using either LC/MS/MS or electron capture gas chromatography. Eleven subjects were randomly selected for the training set using stepwise linear regression to determine relationships between midazolam plasma concentrations and AUC. Validation of the predictive equations was done using the remaining 62 subjects. Mean percent error (MPE), mean absolute error (MAE), and root mean square error (RMSE) were calculated to determine bias and precision. Based on the training set, five models were generated with coefficients of determination ranging from 0.87 to 0.95. Validation showed that MPE, MAE, and RMSE values were acceptable for three of the models. Intrasubject reproducibility was good. In addition, training set datafrom one institution were able to predict data from the other two institutions using other assay techniques. Minimized plasma sampling mayprovide a simpler method for estimating midazolam AUC for CYP3A phenotyping. A limited sampling strategy is more convenient and cost-effective than standard sampling strategies and is applicable to more than one assay technique.
- 1 April 2002
- Vol. 42 (4) , 376-82
Limited sampling strategy to predict AUC of the CYP3A phenotyping probe midazolam in adults: application to various assay techniques.
Midazolam clearance is used to phenotype hepatic CYP3A activity but requires multiple plasma samples following a single intravenous dose. The authors evaluated the use of a limited sampling scheme, using different assay techniques to determine the reproducibility of such a strategy in estimating midazolam AUC. Seventy-three healthy adults received midazolam as a single intravenous bolus dose. At least eight plasma samples were collected from each subject and were assayed using either LC/MS/MS or electron capture gas chromatography. Eleven subjects were randomly selected for the training set using stepwise linear regression to determine relationships between midazolam plasma concentrations and AUC. Validation of the predictive equations was done using the remaining 62 subjects. Mean percent error (MPE), mean absolute error (MAE), and root mean square error (RMSE) were calculated to determine bias and precision. Based on the training set, five models were generated with coefficients of determination ranging from 0.87 to 0.95. Validation showed that MPE, MAE, and RMSE values were acceptable for three of the models. Intrasubject reproducibility was good. In addition, training set datafrom one institution were able to predict data from the other two institutions using other assay techniques. Minimized plasma sampling mayprovide a simpler method for estimating midazolam AUC for CYP3A phenotyping. A limited sampling strategy is more convenient and cost-effective than standard sampling strategies and is applicable to more than one assay technique.
- 15 February 2001
- Published by Physicians Postgraduate Press, Inc in The Journal of Clinical Psychiatry
- Vol. 62 (2) , 127-128
"Dr. Nafzgier and Colleagues Reply"
- 15 February 2001
- Published by Physicians Postgraduate Press, Inc in The Journal of Clinical Psychiatry
- Vol. 62 (2) , 127-128
"Dr. Nafzgier and Colleagues Reply"
- Open Access
- 15 January 2000
- Published by Physicians Postgraduate Press, Inc in The Journal of Clinical Psychiatry
- Vol. 61 (1) , 62-63
Dr. Nafziger and Colleagues Reply
- 15 January 2000
- Published by Physicians Postgraduate Press, Inc in The Journal of Clinical Psychiatry
- Vol. 61 (1) , 62-63
Open AccessDr. Nafziger and Colleagues Reply
- Open Access
- 15 December 1999
- Published by Physicians Postgraduate Press, Inc in The Journal of Clinical Psychiatry
- Vol. 60 (12) , 867-868
Reply to "Improved Outcome in Fluvoxamine-Treated Patients With SSRI-Induced Sexual Dysfunction"
- 15 December 1999
- Published by Physicians Postgraduate Press, Inc in The Journal of Clinical Psychiatry
- Vol. 60 (12) , 867-868
Open AccessReply to "Improved Outcome in Fluvoxamine-Treated Patients With SSRI-Induced Sexual Dysfunction"